Human Osteoprotegerin/TNFRSF11B Antibody Summary
Accession # AAB53709
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Osteoprotegerin/TNFRSF11B Inhibition of TRAIL/ TNFSF10-induced Cyto-toxicity and Neutral-ization by Human Osteoprotegerin/ TNFRSF11B Antibody. In the presence of the metabolic inhibitor actinomycin D (0.5 µg/mL), Recombinant Human Osteoprotegerin/TNFRSF11B Fc Chimera (Catalog # 805-OS) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/ TNFSF10 (50 ng/mL) activity elicited by Recombinant Human Osteoprotegerin/TNFRSF11B Fc Chimera (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human Osteoprotegerin/TNFRSF11B Monoclonal Antibody (Catalog # MAB805). The ND50 is typically 0.15-0.3 µg/mL.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Osteoprotegerin is a member of the TNF receptor superfamily expressed by many cell types. It exists in soluble monomeric and dimeric forms as a decoy receptor for its ligands, TRANCE and TRAIL. Osteoprotegerin functions as an antagonist to RANKL-induced osteoclastogenesis and bone resorption.
Citations for Human Osteoprotegerin/TNFRSF11B Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 4
Filter your results:
Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
Authors: Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM
Mol. Cancer Ther., 2007;6(12):3219-28.
Sample Types: Whole Cells
Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.
Authors: Makrygiannakis D, af Klint E, Catrina SB, Botusan IR, Klareskog E, Klareskog L, Ulfgren AK, Catrina AI
Arthritis Rheum., 2006;54(5):1463-72.
Sample Types: Cell Lysates
Applications: Western Blot
Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome.
Authors: Fonseca JE, Cortez-Dias N, Francisco A, Sobral M, Canhao H, Resende C, Castelao W, Macieira C, Sequeira G, Saraiva F, da Silva JA, Carmo-Fonseca M, Viana Queiroz M
Clin. Exp. Rheumatol., 2005;23(2):185-92.
Sample Types: Whole Tissue
Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
Authors: Mandelin J, Li TF, Hukkanen M, Liljestrom M, Salo J, Santavirta S, Konttinen YT
J. Rheumatol., 2005;32(4):713-20.
Sample Types: Whole Tissue
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human Osteoprotegerin/TNFRSF11B Antibody
Average Rating: 4 (Based on 1 Review)
Have you used Human Osteoprotegerin/TNFRSF11B Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image